Haemonetics (NYSE: HAE) reported Q3 EPS of $0.81, $0.15 better than the analyst estimate of $0.66. Revenue for the quarter came in at $240 million versus the consensus estimate of $225.73 million.

Link to 4Q Earnings Guidance

For earnings history and earnings-related data on Haemonetics (HAE) click here.